文献速递妇科

妇科非癌症手术中的血栓形成与出血风险:系统综述与荟萃分析

Risk of thrombosis and bleeding in gynecologic noncancer surgery: systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2023-12-10

该系统综述与荟萃分析纳入131项观察性研究(共1,741,519例患者),提供50种妇科非癌症手术的症状性静脉血栓栓塞症(VTE)风险和35种手术的需再干预出血风险的程序特异性估计。VTE风险从经阴道取卵术的中位<0.1%到微创骶骨阴道固定术联合子宫切除术的1.5%不等;需再干预出血风险从<0.1%到开腹子宫肌瘤剔除术的4.0%不等。作者认为结果为限制药物性血栓预防用于少数患者提供了有力依据。

要点

  • VTE风险因手术和患者而异,30种(60%)手术<0.5%,10种(20%)0.5%-1.0%,10种(20%)>1.0%。
  • 需再干预出血风险<0.5%者17种(49%),0.5%-1.0%者12种(34%),>1.0%者6种(17%)。
  • 仅在特定患者和手术中VTE风险超过出血风险。

核心结论

  • 妇科非癌症手术的VTE风险因手术和患者而异,仅在特定患者和手术中VTE风险超过出血风险。
  • 尽管多数证据确定性低,结果仍为将药物性血栓预防限制于少数接受妇科非癌症手术的患者提供了有力依据。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase、MEDLINE、Web of Science和Google Scholar,并另行检索血栓预防的随机试验。
  • 纳入≥50例接受妇科非癌症手术的成人观察性研究,报告至少1项指定结局的绝对发生率。
  • 共纳入131项研究(1,741,519例患者),报告50种妇科非癌症手术的VTE风险估计和35种手术的需再干预出血估计。
  • 采用GRADE方法评定证据确定性。

主要发现

  • 症状性VTE风险中位值从经阴道取卵术的<0.1%到微创骶骨阴道固定术联合子宫切除术的1.5%(患者VTE风险组间为1.2%-4.6%)。
  • VTE风险<0.5%者30种(60%)手术,0.5%-1.0%者10种(20%)手术,>1.0%者10种(20%)手术。
  • 需再干预出血风险从经阴道取卵术的<0.1%到开腹子宫肌瘤剔除术的4.0%。
  • 需再干预出血风险<0.5%者17种(49%)手术,0.5%-1.0%者12种(34%)手术,>1.0%者6种(17%)手术。
  • VTE证据确定性一般为中等或低,需再干预出血证据确定性为低或极低。

关键数值与推荐

  • 症状性肺栓塞、症状性深静脉血栓、症状性VTE、需再干预出血(包括再探查和血管栓塞)、导致输血的出血或术后血红蛋白<70 g/L。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • VTE证据确定性一般为中等或低,需再干预出血证据确定性为低或极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to provide procedure-specific estimates of the risk for symptomatic venous thromboembolism and major bleeding in noncancer gynecologic surgeries. DATA SOURCES: We conducted comprehensive searches on Embase, MEDLINE, Web of Science, and Google Scholar. Furthermore, we performed separate searches for randomized trials that addressed the effects of thromboprophylaxis. STUDY ELIGIBILITY CRITERIA: Eligible studies were observational studies that enrolled ≥50 adult patients who underwent noncancer gynecologic surgery procedures and that reported the absolute incidence of at least 1 of the following: symptomatic pulmonary embolism, symptomatic deep vein thrombosis, symptomatic venous thromboembolism, bleeding that required reintervention (including re-exploration and angioembolization), bleeding that led to transfusion, or postoperative hemoglobin level <70 g/L. METHODS: A teams of 2 reviewers independently assessed eligibility, performed data extraction, and evaluated the risk of bias of the eligible articles. We adjusted the reported estimates for thromboprophylaxis and length of follow-up and used the median value from studies to determine the cumulative incidence at 4 weeks postsurgery stratified by patient venous thromboembolism risk factors and used the Grading of Recommendations Assessment, Development and Evaluation approach to rate the evidence certainty. RESULTS: We included 131 studies (1,741,519 patients) that reported venous thromboembolism risk estimates for 50 gynecologic noncancer procedures and bleeding requiring reintervention estimates for 35 procedures. The evidence certainty was generally moderate or low for venous thromboembolism and low or very low for bleeding requiring reintervention. The risk for symptomatic venous thromboembolism varied from a median of <0.1% for several procedures (eg, transvaginal oocyte retrieval) to 1.5% for others (eg, minimally invasive sacrocolpopexy with hysterectomy, 1.2%-4.6% across patient venous thromboembolism risk groups). Venous thromboembolism risk was <0.5% for 30 (60%) of the procedures; 0.5% to 1.0% for 10 (20%) procedures; and >1.0% for 10 (20%) procedures. The risk for bleeding the require reintervention varied from <0.1% (transvaginal oocyte retrieval) to 4.0% (open myomectomy). The bleeding requiring reintervention risk was <0.5% in 17 (49%) procedures, 0.5% to 1.0% for 12 (34%) procedures, and >1.0% in 6 (17%) procedures. CONCLUSION: The risk for venous thromboembolism in gynecologic noncancer surgery varied between procedures and patients. Venous thromboembolism risks exceeded the bleeding risks only among selected patients and procedures. Although most of the evidence is of low certainty, the results nevertheless provide a compelling rationale for restricting pharmacologic thromboprophylaxis to a minority of patients who undergo gynecologic noncancer procedures.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lavikainen LI, Guyatt GH, Kalliala IEJ, et al. Risk of thrombosis and bleeding in gynecologic noncancer surgery: systematic review and meta-analysis. Am J Obstet Gynecol. 2023. PMID: 38072372. doi:10.1016/j.ajog.2023.11.1255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。